MedTrace Logo

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

NCT00006225 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2012-06-06

No results posted yet for this study

Summary

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.

PURPOSE: Randomized phase I/II trial to study the effectiveness of peripheral stem cell transplantation in treating patients who have breast cancer or hematologic cancer.

Conditions

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

recombinant flt3 ligand

BIOLOGICAL

recombinant human thrombopoietin

BIOLOGICAL

recombinant interleukin-3

PROCEDURE

in vitro-treated peripheral blood stem cell transplantation

Sponsors & Collaborators

Principal Investigators

  • Jane N. Winter, MD · Robert H. Lurie Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-11-30
Primary Completion
2004-01-31
Completion
2004-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006225 on ClinicalTrials.gov